Eurospital propose a range of products for identification of patients genetically predisposed to coeliac disease by detecting the following parameters:

  • Genotype
  • Risk
  • Prevention

It does refer to two different PCR methods, developed and made available by Eurospital R&D. Both technologies identify the main HLA Genotypes predisposing to the development of Coeliac Disease.

Eu-Gen System
End-point PCR method on Agarose gel.
Real Time PCR method.


Eurospital also proposes a complete panel of products for the in-vitro diagnosis of coeliac disease.
>> Go to Coeliac Disease page


Eurospital Spa - Via Flavia 122 - 34147 Trieste - P.IVA: 00047510326 - C.S. € 2582000 CF e Reg. Impr. 00047510326 - REA TS 38955
Eurospital © 2021 - Privacy - Site credits